TrialPloS one2023

Biosimilar versus branded enoxaparin to prevent postoperative venous thromboembolism after surgery for digestive tract cancer: Randomized trial.

Chadli Dziri et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.